SVB Wealth LLC Buys 601 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

SVB Wealth LLC increased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,680 shares of the medical research company’s stock after acquiring an additional 601 shares during the period. SVB Wealth LLC’s holdings in Thermo Fisher Scientific were worth $4,607,000 at the end of the most recent quarter.

Other institutional investors also recently modified their holdings of the company. Savant Capital LLC lifted its stake in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after buying an additional 18 shares in the last quarter. 1776 Wealth LLC lifted its stake in Thermo Fisher Scientific by 2.4% in the 4th quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock worth $440,000 after purchasing an additional 19 shares in the last quarter. Sugarloaf Wealth Management LLC lifted its stake in Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after purchasing an additional 19 shares in the last quarter. Rosenberg Matthew Hamilton increased its holdings in shares of Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after buying an additional 19 shares during the last quarter. Finally, Tsfg LLC boosted its stake in shares of Thermo Fisher Scientific by 8.3% during the fourth quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock valued at $132,000 after purchasing an additional 19 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages have weighed in on TMO. Citigroup began coverage on shares of Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a “neutral” rating and a $620.00 target price for the company. Raymond James raised their target price on shares of Thermo Fisher Scientific from $515.00 to $605.00 and gave the company an “outperform” rating in a research note on Thursday, February 1st. The Goldman Sachs Group raised their target price on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Evercore ISI lifted their price objective on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research note on Thursday, April 4th. Finally, TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $601.56.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last three months, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 0.6 %

TMO opened at $554.65 on Wednesday. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75. The company has a fifty day moving average of $571.67 and a two-hundred day moving average of $526.87. The stock has a market capitalization of $211.72 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 2.34 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to analysts’ expectations of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $5.40 earnings per share. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.28%. Thermo Fisher Scientific’s payout ratio is presently 10.10%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.